0.8313 USD
+0.06 (+7.96%)
We assign a fundamental rating of 3 out of 10 to XTNT. XTNT was compared to 184 industry peers in the Health Care Equipment & Supplies industry. XTNT has a bad profitability rating. Also its financial health evaluation is rather negative. XTNT has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year XTNT was profitable.
In the past year XTNT had a positive cash flow from operations.
In the past 5 years XTNT reported 4 times negative net income.
XTNT had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
The Return On Assets of XTNT (-4.43%) is better than 67.93% of its industry peers.
XTNT's Return On Equity of -9.44% is fine compared to the rest of the industry. XTNT outperforms 67.39% of its industry peers.
With a decent Return On Invested Capital value of 0.03%, XTNT is doing good in the industry, outperforming 64.13% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.43% | ||
| ROE | -9.44% | ||
| ROIC | 0.03% |
ROA(3y)-10.3%
ROA(5y)-11.34%
ROE(3y)-20.61%
ROE(5y)-25.18%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
XTNT's Operating Margin of 0.02% is fine compared to the rest of the industry. XTNT outperforms 64.13% of its industry peers.
XTNT's Gross Margin of 60.16% is in line compared to the rest of the industry. XTNT outperforms 59.24% of its industry peers.
XTNT's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 0.02% | ||
| PM (TTM) | N/A | ||
| GM | 60.16% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.35%
GM growth 5Y-2.41%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), XTNT is destroying value.
The number of shares outstanding for XTNT has been increased compared to 1 year ago.
The number of shares outstanding for XTNT has been increased compared to 5 years ago.
XTNT has a worse debt/assets ratio than last year.
2.2 Solvency
XTNT has an Altman-Z score of -0.53. This is a bad value and indicates that XTNT is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -0.53, XTNT perfoms like the industry average, outperforming 41.85% of the companies in the same industry.
XTNT has a Debt/Equity ratio of 0.46. This is a healthy value indicating a solid balance between debt and equity.
XTNT has a Debt to Equity ratio (0.46) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.46 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.53 |
ROIC/WACC0
WACC9.09%
2.3 Liquidity
A Current Ratio of 2.47 indicates that XTNT has no problem at all paying its short term obligations.
XTNT's Current ratio of 2.47 is in line compared to the rest of the industry. XTNT outperforms 50.54% of its industry peers.
A Quick Ratio of 1.16 indicates that XTNT should not have too much problems paying its short term obligations.
XTNT has a Quick ratio of 1.16. This is in the lower half of the industry: XTNT underperforms 71.20% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.47 | ||
| Quick Ratio | 1.16 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 107.69% over the past year.
XTNT shows a strong growth in Revenue. In the last year, the Revenue has grown by 28.44%.
Measured over the past years, XTNT shows a quite strong growth in Revenue. The Revenue has been growing by 12.64% on average per year.
EPS 1Y (TTM)107.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%125%
Revenue 1Y (TTM)28.44%
Revenue growth 3Y28.5%
Revenue growth 5Y12.64%
Sales Q2Q%19.04%
3.2 Future
Based on estimates for the next years, XTNT will show a very strong growth in Earnings Per Share. The EPS will grow by 30.30% on average per year.
XTNT is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.74% yearly.
EPS Next Y121.25%
EPS Next 2Y42.92%
EPS Next 3Y30.31%
EPS Next 5YN/A
Revenue Next Year13.45%
Revenue Next 2Y-1.76%
Revenue Next 3Y1.74%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
XTNT is valuated quite expensively with a Price/Earnings ratio of 83.13.
Compared to the rest of the industry, the Price/Earnings ratio of XTNT indicates a somewhat cheap valuation: XTNT is cheaper than 65.76% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 26.39. XTNT is valued rather expensively when compared to this.
With a Price/Forward Earnings ratio of 163.00, XTNT can be considered very expensive at the moment.
XTNT's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. XTNT is cheaper than 65.22% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.84. XTNT is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 83.13 | ||
| Fwd PE | 163 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of XTNT indicates a somewhat cheap valuation: XTNT is cheaper than 71.20% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 30.11 |
4.3 Compensation for Growth
XTNT's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as XTNT's earnings are expected to grow with 30.30% in the coming years.
PEG (NY)0.69
PEG (5Y)N/A
EPS Next 2Y42.92%
EPS Next 3Y30.31%
5. Dividend
5.1 Amount
No dividends for XTNT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NYSEARCA:XTNT (12/22/2025, 11:08:09 AM)
0.8313
+0.06 (+7.96%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners57.17%
Inst Owner Change-8.18%
Ins Owners16.56%
Ins Owner Change12.22%
Market Cap116.38M
Revenue(TTM)117.27M
Net Income(TTM)-4.58M
Analysts85
Price Target1.53 (84.05%)
Short Float %0.02%
Short Ratio0.06
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)198.04%
Min EPS beat(2)100%
Max EPS beat(2)296.08%
EPS beat(4)2
Avg EPS beat(4)77.12%
Min EPS beat(4)-56.86%
Max EPS beat(4)296.08%
EPS beat(8)3
Avg EPS beat(8)73.86%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)7.07%
Min Revenue beat(2)3.39%
Max Revenue beat(2)10.74%
Revenue beat(4)2
Avg Revenue beat(4)1.19%
Min Revenue beat(4)-6.52%
Max Revenue beat(4)10.74%
Revenue beat(8)6
Avg Revenue beat(8)5.84%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-14.29%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)150%
EPS NY rev (3m)225%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)2.58%
Revenue NY rev (3m)2.58%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 83.13 | ||
| Fwd PE | 163 | ||
| P/S | 0.91 | ||
| P/FCF | N/A | ||
| P/OCF | 77.54 | ||
| P/B | 2.4 | ||
| P/tB | 3.45 | ||
| EV/EBITDA | 30.11 |
EPS(TTM)0.01
EY1.2%
EPS(NY)0.01
Fwd EY0.61%
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)0.01
OCFY1.29%
SpS0.91
BVpS0.35
TBVpS0.24
PEG (NY)0.69
PEG (5Y)N/A
Graham Number0.28
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.43% | ||
| ROE | -9.44% | ||
| ROCE | 0.04% | ||
| ROIC | 0.03% | ||
| ROICexc | 0.03% | ||
| ROICexgc | 0.04% | ||
| OM | 0.02% | ||
| PM (TTM) | N/A | ||
| GM | 60.16% | ||
| FCFM | N/A |
ROA(3y)-10.3%
ROA(5y)-11.34%
ROE(3y)-20.61%
ROE(5y)-25.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.35%
GM growth 5Y-2.41%
F-Score5
Asset Turnover1.23
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.46 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 4.97 | ||
| Cap/Depr | 97.07% | ||
| Cap/Sales | 3.39% | ||
| Interest Coverage | 0.01 | ||
| Cash Conversion | 33.42% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.47 | ||
| Quick Ratio | 1.16 | ||
| Altman-Z | -0.53 |
F-Score5
WACC9.09%
ROIC/WACC0
Cap/Depr(3y)93.26%
Cap/Depr(5y)102.58%
Cap/Sales(3y)2.72%
Cap/Sales(5y)2.97%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)107.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%125%
EPS Next Y121.25%
EPS Next 2Y42.92%
EPS Next 3Y30.31%
EPS Next 5YN/A
Revenue 1Y (TTM)28.44%
Revenue growth 3Y28.5%
Revenue growth 5Y12.64%
Sales Q2Q%19.04%
Revenue Next Year13.45%
Revenue Next 2Y-1.76%
Revenue Next 3Y1.74%
Revenue Next 5YN/A
EBIT growth 1Y100.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year220.68%
EBIT Next 3Y42.24%
EBIT Next 5YN/A
FCF growth 1Y74.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y116.46%
OCF growth 3YN/A
OCF growth 5YN/A
XTANT MEDICAL HOLDINGS INC / XTNT FAQ
What is the fundamental rating for XTNT stock?
ChartMill assigns a fundamental rating of 3 / 10 to XTNT.
What is the valuation status of XTANT MEDICAL HOLDINGS INC (XTNT) stock?
ChartMill assigns a valuation rating of 4 / 10 to XTANT MEDICAL HOLDINGS INC (XTNT). This can be considered as Fairly Valued.
How profitable is XTANT MEDICAL HOLDINGS INC (XTNT) stock?
XTANT MEDICAL HOLDINGS INC (XTNT) has a profitability rating of 3 / 10.
What is the valuation of XTANT MEDICAL HOLDINGS INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for XTANT MEDICAL HOLDINGS INC (XTNT) is 83.13 and the Price/Book (PB) ratio is 2.4.